Nonmelanoma Skin Cancer Mortality (1988-2000)

Lewis, Kevan G.; Weinstock, Martin A.

doi:10.1001/archderm.140.7.837

Cited by 102 publications

(42 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from Scotland show an ASMR for the same years as this study as 0.67/ 100,000 for men and 0.29/100,000 for females [19]. Lewis and Weinstock [17] calculated an ASMR of 0.47/100,000 (combined males and females) for all NMSC deaths in Rhode Island for the years 1988-2000. The higher mortality rates in WA are consistent with the much higher incidence.…”

Section: Discussionmentioning

confidence: 74%

“…Two consecutive studies of NMSC deaths in Rhode Island (one from 1978-1987 and one from 1988-2000) found that a significant proportion of deaths attributed to NMSC were miscoded [16,17]. The earlier study reported over 50% of NMSC cases were miscoded, while the later study used a more rigorous definition to report that 44% of confirmed NMSC deaths and 34% of probable NMSC deaths were miscoded [16,17]. A previous Australian study reported that 23% of NMSC deaths were misclassified, the majority of these deaths being due to AIDS-related Kaposi sarcoma [14].…”

Section: Discussionmentioning

confidence: 99%

“…Of those that were correctly identified, the majority of deaths had occurred in the elderly, predominantly in elderly men. Two studies of NMSC deaths in Rhode island (one from 1978-1987 and one from 1988-2000) also found that a significant proportion of deaths attributed to NMSC were mis-coded [16,17].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Deaths from non-melanoma skin cancer in Western Australia

Girschik

Fritschi

Threlfall

et al. 2008

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Deaths from non-melanoma skin cancer in Western Australia

Girschik

Fritschi

Threlfall

et al. 2008

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…2,3 Although less common than BCC, squamous cell carcinoma (SCC) of the skin carries a Ͼ10-fold higher risk of metastasis and mortality. 4 Surgical treatment of BCC and SCC is frequently disfiguring, and local recurrence is not uncommon. Clearly, BCC and SCC constitute serious health problems.…”

mentioning

confidence: 99%

Differential ErbB1 Signaling in Squamous Cell versus Basal Cell Carcinoma of the Skin

Rittié

Kansra

Stoll

et al. 2007

The American Journal of Pathology

View full text Add to dashboard Cite

In this study , we examined ErbB1 signaling in human basal and squamous cell carcinomas (BCC and SCC) of the skin in vivo. We used enzyme-linked immunosorbent assay , laser capture microdissection-coupled real-time reverse transcriptase-polymerase chain reaction , and immunohistochemistry to assess expression and activation levels of ErbB1 protein , ligands , and potential downstream effectors , in BCC and SCC tumors , stroma , and adjacent epidermis. Although total ErbB1 protein and mRNA were similar in cancerous and normal skin , we found that ErbB1 activation (phospho-Tyr 1068 ) was greater in bulk SCC versus BCC or normal skin. In addition , three ErbB1 ligand transcripts (amphiregulin , heparin-binding epidermal growth factorlike growth factor , and transforming growth factor-␣) were up-regulated in tumor cells of SCC but not BCC. Expression of these ligands was also increased in asymptomatic epidermis adjacent to both SCC and BCC , relative to normal skin. Interestingly , betacellulin transcript levels were inversely regulated compared with the other ligands. Consistently , downstream ErbB1 effectors (Erk1/2 and Akt) were activated in tumor cells of SCC but not of BCC and in adjacent epidermis of both BCC and SCC. These results demonstrate that ErbB1 signaling is hyperactive in tumor cells of SCC but not of BCC and in nearby asymptomatic epidermis of both tumor types. Our results suggest that targeting ErbB1 signaling might be of benefit in the treatment of

show abstract

“…[1][2][3] Mortality rates from a population-based follow-back study for nonmelanoma skin cancer was 0.91 per 100,000 per year. 4 However, unlike other cancers in which end points focus on mortality, morbidity is critical to understanding the burden of disease for KCs, as these skin cancers are generally not fatal, but may lead to severe disfigurement and related complications.…”

Section: Introductionmentioning

confidence: 99%